- Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials.
- Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data.
- The readout shows efficacy in a subgroup, underlining validity of the proposed pathway and drug candidate ATH-1017, and I expected this would happen.
- The company's shares are falling severely on the primary endpoint miss.
- Simply stated, if the primary endpoint would have been cognition in the monotherapy group, then the results would have been seen as successful, which is why I believe there is potential to be a new Alzheimer's drug in the making here.
For further details see:
Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug